Evidence map›Paper›PMID 38069037›Full record

ArticleInternational journal of molecular sciences2023

Synthesis and Characterization of a New Class of Chromene-Azo Sulfonamide Hybrids as Promising Anticancer Candidates with the Exploration of Their EGFR,

Fawzia F Alblewi, Mosa H Alsehli, Zainab M Hritani, Areej Eskandrani, Wael H Alsaedi, Majed O Alawad, Ahmed A Elhenawy, Hanaa Y Ahmed, Mohamed S A El-Gaby, Tarek H Afifi and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Fawzia F AlblewiChemistry Department, College of Science, Taibah University, Medina 30002, Saudi Arabia.
Mosa H AlsehliChemistry Department, College of Science, Taibah University, Medina 30002, Saudi Arabia.
Zainab M HritaniChemistry Department, College of Science, Taibah University, Medina 30002, Saudi Arabia.
Areej EskandraniChemistry Department, College of Science, Taibah University, Medina 30002, Saudi Arabia.
Wael H AlsaediChemistry Department, College of Science, Taibah University, Medina 30002, Saudi Arabia.
Majed O AlawadCenter of Excellence for Nanomaterials for Clean Energy Applications, King Abdulaziz City for Science and Technology (KACST), Riyadh 12354, Saudi Arabia.ORCID 0000-0001-7500-7694
Ahmed A ElhenawyChemistry Department, Faculty of Science, Al-Azhar University, Nasr City 11884, Egypt.ORCID 0000-0003-2893-0376
Hanaa Y AhmedThe Regional Center for Mycology and Biotechnology, Al-Azhar University, Nasr City 11884, Egypt.ORCID 0000-0001-7987-7769
Mohamed S A El-GabyChemistry Department, Faculty of Science, Al-Azhar University, Nasr City 11884, Egypt.
Tarek H AfifiChemistry Department, College of Science, Taibah University, Medina 30002, Saudi Arabia.ORCID 0000-0002-8029-4840
Rawda M OkashaChemistry Department, College of Science, Taibah University, Medina 30002, Saudi Arabia.
Taibah University · SAAl-Azhar University · EGKing Abdulaziz City for Science and Technology · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, novel selective antitumor compounds were synthesized based on their fundamental pharmacophoric prerequisites associated with EGFR inhibitors. A molecular hybridization approach was employed to design and prepare a range of 4

Indexed as

Antineoplastic AgentsBenzopyransCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorErbB ReceptorsMatrix Metalloproteinase 2Molecular Docking SimulationMolecular StructureProtein Kinase InhibitorsSorafenibStructure-Activity RelationshipSulfonamidesAntineoplastic AgentsBenzopyransErbB ReceptorsMatrix Metalloproteinase 2Protein Kinase InhibitorsSorafenibSulfonamides4H-chromeneEGFRMMP2molecular dockingsulfonamide

Identifiers

PMID38069037
PMCPMC10706804
OpenAlexW4388971502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.